Endowments Circle Secondhand Life Settlement Portfolios for Yield

The Quiet Accumulation

University endowments and private foundations are increasingly looking at life settlement portfolios not as fringe curiosities but as yield-generating assets worth serious allocation. The asset class, which involves purchasing existing life insurance policies from policyholders who no longer need or can afford them, has spent decades at the edge of institutional finance. That positioning is changing.

How Life Settlements Generate Returns

The mechanics are straightforward. A policyholder – often elderly, often facing liquidity needs – sells their life insurance policy to an investor for a lump sum greater than the cash surrender value the insurer would pay but less than the death benefit. The buyer then assumes premium payments and eventually collects the death benefit when the insured passes. The spread between total premiums paid and the death benefit collected, discounted to present value, constitutes the investor’s return.

What makes life settlements attractive to endowments specifically is their near-zero correlation to equity markets. During a broad market selloff, the actuarial clock on a portfolio of policies does not change. Mortality rates do not respond to Federal Reserve rate decisions or corporate earnings misses. That decoupling is genuinely rare in modern portfolio construction, where most alternative assets – private equity, real estate, even infrastructure debt – still carry some tail exposure to credit conditions and growth cycles.

The secondary market for life insurance policies has matured considerably since its early, reputationally messy days in the 1990s. Broker-dealers, specialty fund managers, and institutional custodians have built infrastructure around policy valuation, medical underwriting standards, and portfolio diversification. Endowments are not buying individual policies; they are buying into funds that hold hundreds or thousands of policies, underwritten using life expectancy reports from independent medical actuaries. That scale reduces the idiosyncratic risk of any single insured outliving projections dramatically.

Yield targets in this space typically range from mid-single digits to low double digits depending on the mix of policy face values, remaining premium loads, and average life expectancy of the insured pool. For an endowment managing to a five percent annual spending rule, a life settlement sleeve generating eight to ten percent gross returns – even after fund fees – fills a meaningful gap that traditional fixed income has struggled to cover in a compressed-rate environment. The asset also comes with a defined outcome: unlike a corporate bond that can default or a stock that can go to zero on bad management, a life insurance policy from a rated carrier will pay. The uncertainty is timing, not existence of the payment.

Why Endowments Are Circling Now

The timing of this renewed institutional interest is not accidental. Endowments spent the last decade chasing yield in private credit, venture capital, and real assets, many of which are now crowded. Entry valuations in private equity buyouts are high. Direct lending spreads have compressed as more capital chases fewer quality borrowers. Real estate faces structural headwinds in office and retail. Life settlements, by contrast, have not experienced the same capital inflows, partly because of lingering reputational concerns and partly because the asset requires specialized knowledge to evaluate properly.

Smaller endowments – those managing between $500 million and $2 billion – are showing particular interest. These institutions lack the scale to build proprietary deal flow in infrastructure or timberland, and their private equity allocations often come through funds-of-funds with layered fee structures that eat returns. A life settlement fund with a transparent fee arrangement and predictable cash flows presents a cleaner value proposition at their scale.

The regulatory environment has also stabilized. Life settlement transactions are now licensed and regulated in the majority of U.S. states, with disclosure requirements designed to protect policyholders and reduce fraud. That legal scaffolding matters to endowment investment committees and boards, which carry fiduciary obligations and have little appetite for reputational risk. A clearly regulated secondary market is easier to approve than one operating in ambiguous legal territory.

Liquidity remains the honest drawback. Life settlement funds typically impose multi-year lock-up periods, and secondary trading in fund interests is thin. An endowment that needs to liquidate quickly – perhaps to fund a capital campaign draw or cover an unexpected operating shortfall – cannot count on a life settlement position the way it can count on a public bond holding. Portfolio construction decisions around this asset class require careful liquidity tiering. Endowments that have built robust cash and near-liquid reserves can absorb a three-to-five-year lock-up more comfortably than those running lean.

There is also an ongoing debate about life expectancy modeling accuracy. Independent medical underwriters use current health data and mortality tables to project when insured individuals will die, and the entire return calculation rests on those projections. When life expectancy extensions – driven by advances in cancer treatment or cardiac care – outpace model assumptions, portfolios generate lower-than-projected returns because premium payments extend longer than expected. Some fund managers have been criticized for using overly aggressive mortality assumptions that flattered projected returns on paper. Endowment investment officers are spending more time stress-testing those assumptions before committing capital.

Allocation Sizing and Portfolio Fit

Most endowments entering this space are treating life settlements as a satellite allocation rather than a core holding – typically between one and three percent of total portfolio value. At that sizing, the diversification benefit is real without creating concentration risk or liquidity problems. The allocation often sits within a broader alternatives bucket alongside real assets and private credit, justified on the basis of its non-correlated return stream rather than its absolute return potential alone.

The deeper question for investment committees is whether the asset class scales gracefully as more institutional capital arrives. If endowments collectively increase demand for life settlement portfolios, pricing for policies in the secondary market rises, compressing the margin available to buyers. The policyholder gets more, which is arguably a fair outcome, but the investor earns less. Some fund managers argue the supply of policies will grow as the U.S. population ages and more seniors find themselves holding large insurance policies they no longer need – but whether that supply growth keeps pace with institutional demand is the unresolved tension sitting at the center of every pitch deck in this space right now.